Novartis announces the company’s fourth quarter and 2016 full year financial results.

calendar-IconJanuary 25, 2017

Basel, Switzerland

This morning, Novartis CEO Joe Jimenez announced fourth quarter and full year 2016 results. In his remarks Jimenez said: “Novartis delivered a solid performance in 2016, absorbing Gleevec US loss of exclusivity while investing in key launches and the Alcon Division turnaround. Cosentyx reached blockbuster status in 2016, and the conditions are now in place for Entresto sales to accelerate in 2017. We made major strides in advancing our pipeline, executing our bolt-on M&A strategy and implementing our new focused organization. Today we are proposing an increase in our dividend and initiating a share buyback of up to USD 5 billion. Additionally, we are reviewing options for the Alcon Division to maximize shareholder value.”

$2016 At A Glance

2016 At A Glance

Annual Report 2016

The Novartis Annual Report 2016 reviews the company’s strategy and annual performance.

Visit the Annual Report

 

Form 20-F 2016

Documents Novartis results in line with requirements of the US Securities and Exchange Commission (SEC).

English (PDF 3 MB)